10-K: Tvardi Therapeutics Faces Going Concern Doubt Amidst Mixed Clinical Results

Tvardi Therapeutics reported a reduced net loss in 2025 but faces substantial doubt about its ability to continue as a going concern, following a failed IPF trial and delays in its key HCC program.

Summary

• Tvardi Therapeutics, Inc. (TVRD) is a clinical-stage biopharmaceutical company focused on oral small molecule therapies targeting STAT3 for inflammatory and proliferative diseases.
• The company completed a merger with Cara Therapeutics, Inc. on April 15, 2025, acquiring approximately $23.9 million in net assets.
• Net loss for the year ended December 31, 2025, was $18.2 million, an improvement from $29.4 million in 2024.
• As of December 31, 2025, the accumulated deficit was $110.5 million, and cash and cash equivalents totaled $20.7 million, with $10.1 million in short-term investments.
• Management has concluded that there is substantial doubt about the company's ability to continue as a going concern, necessitating additional funding.
• The Phase 2 clinical trial of TTI-101 in idiopathic pulmonary fibrosis (IPF) did not meet its goals, as reported in October 2025.
• A post-hoc exploratory analysis of the IPF trial, excluding certain patients, showed TTI-101 treatment led to greater reductions in fibrosis score (9.4% vs. 2.4% for placebo) and a 4.5-fold greater decline in IL-6 compared to placebo.
• The REVERT LIVER CANCER Phase 1b/2 clinical trial for TTI-101 in hepatocellular carcinoma (HCC) had its anticipated data readout extended from the first half of 2026 to the second half of 2026 to allow data to mature and optimize dosing.
• Preliminary efficacy data from the HCC trial's Phase 1b portion showed a 67% disease control rate (DCR) for TTI-101 monotherapy (Cohort A) and a 93% DCR for TTI-101 in combination with atezolizumab and bevacizumab (Cohort C).
• An Investigational New Drug (IND) application for TTI-109, a prodrug of TTI-101, was accepted by the FDA in June 2025, and a Phase 1 trial in healthy volunteers was initiated.
• Material weaknesses in internal control over financial reporting were identified as of December 31, 2025, including an ineffective control environment, insufficient finance personnel, lack of formalized risk assessment, and inadequate review processes.
• The company does not own composition of matter patent protection for the TTI-101 molecule, relying instead on method-of-use, manufacturing, and pharmaceutical composition patents.
• Legal proceedings related to the Cara Merger, challenging proxy statement disclosures, were resolved by August 15, 2025, with supplemental disclosures and a mootness fee.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this filing with a mixed-to-negative sentiment. While there's progress in the pipeline and some positive signals from post-hoc analysis, the 'going concern' doubt and the primary failure of the IPF trial, coupled with delays in the HCC program, present significant financial and operational challenges.

Positives

• Net loss decreased to $18.2 million in 2025 from $29.4 million in 2024, indicating some cost management or reduced activity.
• The merger with Cara Therapeutics, Inc. in April 2025 brought approximately $23.9 million in net assets, providing a capital infusion.
• TTI-109, a next-generation STAT3 inhibitor, had its IND application accepted by the FDA in June 2025, and a Phase 1 trial in healthy volunteers was initiated, demonstrating pipeline progression.
• TTI-101 received Fast Track designation from the FDA for hepatocellular carcinoma (HCC), potentially accelerating its development and review process.
• Post-hoc analysis of the REVERT IPF Phase 2 trial, despite not meeting its primary goals, showed TTI-101 treatment led to a 7 percentage point greater reduction in fibrosis score and a 4.5-fold greater decline in IL-6 compared to placebo in a subset of patients, providing human clinical proof of concept for the STAT3 inhibition platform.
• Preliminary efficacy data from the REVERT LIVER CANCER Phase 1b/2 trial in HCC showed encouraging disease control rates, including 93% in the treatment-naïve combination arm (Cohort C) and 67% in the monotherapy arm (Cohort A), with one patient demonstrating potential resensitization to ICI therapy.
• The company possesses a robust intellectual property portfolio, including 12 patent families for TTI-101 and 4 for TTI-109, covering methods of use, formulations, and the TTI-109 compound itself, with expirations extending to 2046.

Negatives

• The REVERT IPF Phase 2 clinical trial for TTI-101 did not meet its goals, leading to uncertainty regarding future development in this indication.
• High discontinuation rates were observed in the TTI-101 IPF trial (56.7% for 400mg and 62.1% for 800mg arms) primarily due to gastrointestinal adverse events, especially with concurrent nintedanib.
• Early safety data from the TTI-101 HCC combination arms revealed a higher-than-expected incidence of pulmonary-related treatment-emergent adverse events, leading to protocol modifications for lower dosages and intermittent schedules.
• The company has incurred significant net losses since inception and reported an accumulated deficit of $110.5 million as of December 31, 2025.
• Management has identified substantial doubt about the company's ability to continue as a going concern, indicating a critical need for additional funding.
• The anticipated data readout from the REVERT LIVER CANCER Phase 1b/2 clinical trial for TTI-101 in HCC was extended from the first half of 2026 to the second half of 2026.
• Material weaknesses were identified in the design and operating effectiveness of internal control over financial reporting, including an ineffective control environment and insufficient finance personnel.
• The company does not own or in-license any composition of matter patent protection for the TTI-101 molecule, relying on less comprehensive method-of-use and pharmaceutical composition patents.
• The company has not generated any revenue to date and does not expect to generate significant product revenue for several years, if ever.

Risks

• Incurred significant net losses since inception and expects to continue incurring losses, with no revenue generated to date.
• Financial condition raises substantial doubt about the ability to continue as a going concern.
• Requires substantial additional capital to fund operations; inability to raise capital could force delays or elimination of programs.
• Business is highly dependent on the success of product candidates TTI-101 and TTI-109, which require significant additional development.
• Preclinical and clinical development is a lengthy, complex, and expensive process with uncertain outcomes, and product candidates can fail at any stage.
• Ongoing and future clinical trials may reveal significant adverse events or unexpected drug-drug interactions, delaying or preventing regulatory approval.
• Interim, blinded, and preliminary data from clinical trials may change as more patient data become available or additional analyses are conducted.
• Positive results from early studies are not necessarily predictive of later clinical trial results.
• Difficulties in enrolling patients in clinical trials could delay or adversely affect development activities.
• The design or execution of ongoing and future clinical trials may not support marketing approval.
• May not be successful in identifying or discovering additional product candidates in the future.
• Limited resources necessitate allocation decisions that may prove wrong or forgo more promising opportunities.
• Future clinical trials may be conducted outside the U.S., and the FDA may not accept data from such trials.
• Orphan drug designation does not guarantee faster review or approval, nor does it prevent competition from different drugs for the same condition.
• Fast Track designation does not assure faster development, review, or marketing approval.
• Even if approved, product candidates may fail to achieve market acceptance by physicians, patients, and third-party payors.
• Faces substantial competition from larger pharmaceutical companies and other entities with greater resources.
• Product liability lawsuits could result in substantial financial or other liabilities and limit commercialization.
• The regulatory approval process is highly uncertain and subject to ongoing obligations and review, potentially leading to labeling restrictions or market withdrawal.
• Coverage and reimbursement may be limited or unavailable, or pricing unfavorable, making it difficult to sell products profitably.
• Changes to current healthcare laws and reform measures could increase costs and affect pricing and reimbursement.
• Operations and relationships with healthcare providers are subject to anti-bribery, anti-kickback, fraud and abuse, and transparency laws.
• Failure to comply with environmental, health, and safety laws could result in fines or penalties.
• Future growth depends on penetrating foreign markets, subject to additional regulatory burdens and risks.
• Governments outside the U.S. tend to impose strict price controls.
• Inadequate funding for the FDA and other government agencies could hinder their ability to review and approve products.
• Subject to U.S. and foreign anti-corruption, anti-money laundering, export control, sanctions, and other trade laws.
• Commercial success depends on obtaining, maintaining, enforcing, and protecting intellectual property, which is difficult and costly.
• No composition of matter patent protection for TTI-101 molecule, relying on less robust method-of-use and pharmaceutical composition patents.
• Pending patent applications may not issue, or issued patents may be challenged, invalidated, or circumvented.
• Intellectual property licensed from third parties (e.g., BCM) may be subject to retained rights or government march-in rights.
• Patent terms may be inadequate to protect competitive position for a sufficient amount of time.
• Changes in the interpretation of patent law could diminish the value of patents.
• Inability to seek or obtain patent protection throughout the world or enforce it once obtained.
• May be sued for infringing intellectual property rights of third parties, leading to costly litigation or inability to commercialize.
• Others may challenge inventorship or claim ownership interest in intellectual property.
• Inability to protect the confidentiality of trade secrets would harm business and competitive position.
• May need to acquire or license additional intellectual property from third parties, which may not be available on reasonable terms.
• Reliance on third parties (CROs, CDMOs) to conduct preclinical studies, clinical trials, and manufacturing, with limited control over their activities.
• Changes in manufacturing methods or formulation may result in additional costs or delays.
• Supply of research, preclinical, and clinical materials may become limited or interrupted, especially from single-source vendors or foreign jurisdictions.
• Suppliers and collaborators may require assurances of financial resources and stability.
• Difficulties in managing growth, including hiring and retaining personnel and expanding capabilities.
• No internal marketing and sales organization, requiring significant investment to develop these capabilities or reliance on third parties.
• Loss of key management personnel or failure to recruit skilled personnel could impair development.
• Employees, contractors, and partners may engage in misconduct or improper activities.
• Adverse effects from natural disasters or disruptions to facilities and supply chain.
• Market price of common stock is expected to be volatile.
• Incurring significant costs and demands on management as a public company.
• Anti-takeover provisions in charter documents and Delaware law could make acquisition more difficult.
• Exclusive forum provisions could limit stockholders' ability to obtain a favorable judicial forum.
• No anticipation of paying cash dividends in the foreseeable future.
• An active trading market for common stock may not develop or be sustained.
• Future sales of shares by existing stockholders could cause stock price to decline.
• If equity research analysts do not publish research or publish unfavorable reports, stock price and trading volume could decline.
• Failure to maintain proper and effective internal controls could impair ability to produce accurate financial statements.
• Issuance of additional capital stock will dilute other stockholders.
• Subject to SEC requirements applicable to reporting shell company business combinations, leading to more stringent reporting and resale restrictions.
• May become involved in securities litigation.
• Unfavorable global economic conditions could adversely affect business.
• Adverse developments affecting the financial services industry could impair access to funding.
• Increasing use of social media platforms presents new risks and challenges related to information disclosure and regulatory compliance.

Future Outlook

The company expects to report topline data from the TTI-109 Phase 1 trial in the second quarter of 2026, after which it intends to announce the clinical indication for Phase 2 development. Topline data from the REVERT LIVER CANCER Phase 1b/2 trial for TTI-101 in HCC is anticipated in the second half of 2026, which will inform pivotal development strategy. The company plans to continue investing in research and development, expand its pipeline into additional inflammatory and proliferative indications, and build out commercialization capabilities. Significant operating losses are expected to continue for the foreseeable future, and substantial additional funding will be required to finance ongoing and planned clinical trials.

Management Comments

• "We believe our oral small molecule STAT3 inhibitors have the potential for broad applicability across a diverse range of inflammatory and proliferative diseases."
• "We believe a central strength of our platform is the alignment between preclinical findings and clinical observations to date, with effects of STAT3 inhibition observed in preclinical studies recapitulated in human data."
• "We believe TTI-101 is a novel therapeutic candidate that could offer a much-needed treatment option in HCC."
• "We believe resensitizing patients to ICI therapy has the potential to further improve survival and quality of life for patients with HCC."
• "Management has determined that its present capital resources as of December 31, 2025 will not be sufficient to fund its planned operations for at least one year from the issuance date of the consolidated financial statements, included elsewhere in this Annual Report on Form 10-K, which raises substantial doubt as to our ability to continue as a going concern."

Industry Context

StockSavvy.ai notes that Tvardi Therapeutics is operating in highly competitive biopharmaceutical industries, focusing on STAT3 inhibition, a historically challenging target. The company's strategy to target inflammatory and proliferative diseases, including IPF and HCC, places it against established therapies and numerous investigational products from larger pharmaceutical and biotechnology companies. The high unmet need in HCC, despite existing ICI combination therapies, presents both a significant commercial opportunity and a challenge for Tvardi to demonstrate superior efficacy and safety. The broader industry trend towards cost containment and evolving regulatory landscapes, including potential changes to drug pricing and data exclusivity in the EU, adds complexity to Tvardi's commercialization prospects. The increasing prevalence of cybersecurity threats and the evolving regulatory environment for AI also represent significant operational challenges for companies in this sector.

Comparison to Industry Standards

• In the REVERT IPF Phase 2 trial, the mean FVC decline in pooled TTI-101 treated patients (-15mL) was less than expected compared to historical placebo groups from comparable IPF trials, such as the Phase 2 bexotegrast study's -110.7mL placebo FVC change at 12 weeks.
• The Phase 1 monotherapy trial of TTI-101 in advanced solid tumors, including HCC, demonstrated an Overall Response Rate (ORR) exceeding current second-line standard of care for HCC.
• The current first-line standard of care for HCC, the combination of atezolizumab and bevacizumab (marketed by Genentech), resulted in an ORR of 27% with a median duration of 18.1 months in Roche's IMBrave150 clinical trial, which Tvardi's preliminary HCC data aims to improve upon, particularly with its 93% DCR in Cohort C of the REVERT LIVER CANCER trial.
• Second-line therapies for HCC, primarily anti-angiogenic agents like tyrosine kinase inhibitors and anti-VEGF therapies, offer modest expected clinical benefit and have high rates of discontinuations due to severe adverse events, highlighting the unmet need Tvardi aims to address.

Corporate Governance

Legal Proceedings

• Between December 20, 2024, and March 19, 2025, Cara Therapeutics, Inc. received 13 demands and three draft complaints from purported stockholders challenging disclosures in the proxy statement/prospectus related to the merger. These claims asserted violations of Sections 14(a) and 20(a) of the Securities Exchange Act of 1934 and New York state law.
• On March 5 and March 6, 2025, two lawsuits (Joseph Clark v. Cara Therapeutics, Inc., et al. and Michael Kent v. Cara Therapeutics, Inc., et al.) were filed by purported stockholders of Cara in the Supreme Court of the State of New York, County of New York, also challenging merger disclosures.
• Cara Therapeutics, Inc. filed supplemental disclosures on March 24, 2025, to moot the disclosure claims, and the matters were resolved by August 15, 2025, with a mootness fee demand.
• On March 6, 2026, Shaheen Wirk, Palkon Holdings, LLC, and Palkon TT Holdings, LLC filed a complaint in the Supreme Court of the State of New York, County of New York, alleging breach of the Registration Rights Agreement, dated April 15, 2025, by failing to timely cause a resale registration statement to be declared effective.

Related Party Transactions

• The company has license agreements with Baylor College of Medicine (BCM) for exclusive use of patent rights related to TTI-101 and TTI-109. These agreements include annual maintenance fees ($30,000 to $50,000 per year per license), milestone payments (up to $2.2 million aggregate for BCM First Agreement, up to $1.225 million aggregate for BCM Second Agreement), and low-single-digit percentage royalties on net sales.
• The company is obligated to pay royalties to its co-founders, David J. Tweardy, M.D. and Ron DePinho, M.D., in an amount equal to 1% each on the worldwide net sales of TTI-101 and any derivative formulations (Royalty Bearing Products). These obligations last for the later of patent coverage or 15 years after first commercial sale.

Stakeholder Impact

• Shareholders face significant dilution risk from future equity offerings needed to fund operations, and the stock price is expected to be volatile due to clinical trial outcomes and financial uncertainties. No cash dividends are anticipated in the foreseeable future.
• Employees benefit from equity incentive plans, a new severance and change in control plan, and comprehensive health and safety benefits, but face intense competition for skilled personnel and potential impacts from management's focus on growth activities.
• Patients could potentially benefit from novel oral therapies for inflammatory and proliferative diseases if product candidates achieve regulatory approval, but face risks associated with clinical trial failures and adverse events.
• Creditors may face increased risk due to the company's substantial doubt about its ability to continue as a going concern and its ongoing need for additional capital.
• Suppliers and contract manufacturers face risks related to the company's financial stability and potential disruptions in the supply chain, especially from single-source or foreign vendors.

Next Steps

• Report topline data from the TTI-109 Phase 1 trial in healthy volunteers in the second quarter of 2026.
• Announce the clinical indication in which TTI-109 will advance into Phase 2 development after reporting Phase 1 data.
• Report topline data from the REVERT LIVER CANCER Phase 1b/2 clinical trial for TTI-101 in HCC in the second half of 2026.
• Use the REVERT LIVER CANCER data to inform the pivotal development strategy for TTI-101 in HCC.
• Continue to evaluate the results from the REVERT IPF trial to inform potential future development decisions for TTI-101 in IPF.
• Advance TTI-109 into Phase 2 development in a selected inflammatory and/or proliferative indication.
• Expand the pipeline into additional indications where STAT3 activation plays a central role in disease pathogenesis.
• Evaluate and pursue tailored strategies to maximize the impact of product candidates and benefit to patients, including potential strategic partnerships.
• Build necessary sales, marketing, and commercialization capabilities over time.
• Remediate identified material weaknesses in internal control over financial reporting by designing new procedures and controls, establishing a monitoring program, and adding experienced personnel.
• Seek additional funding through equity offerings, debt financings, or strategic alliances to support ongoing operations and clinical trials.

Key Dates

Recommendation

The company presents a high-risk, high-reward profile. The 'going concern' warning and the failure of the IPF trial are significant negatives, indicating substantial financial and clinical hurdles. However, the promising preliminary data in HCC, the Fast Track designation, and the progression of TTI-109 into Phase 1 suggest potential for future value creation. A 'hold' recommendation acknowledges the severe risks and capital needs while recognizing the speculative upside of its pipeline in areas of high unmet medical need. Investors should monitor upcoming clinical data readouts and capital raising efforts closely.

Keywords

STAT3 inhibitors, Hepatocellular Carcinoma, HCC, Idiopathic Pulmonary Fibrosis, IPF, TTI-101, TTI-109, Clinical-stage biopharmaceutical, SEC filing, 10-K, Drug development, Oncology, Inflammatory diseases, Prodrug, Clinical trials, Regulatory approval, Biotechnology, Financial results, Going concern, Intellectual property, Merger, Nasdaq Capital Market